Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment
Chaorui Huang*1, Lars-Olof Wahlund1, Leif Svensson2, Bengt Winblad1 and Per Julin1

Address: 1Karolinska Institutet, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research (NEUROTEC), Divison of Geriatric Medicine, Huddinge University Hospital, Sweden and 2Karolinska Institutet, Department of Hospital Physics, Huddinge University Hospital, Sweden
E-mail: Chaorui Huang* - chaorui.huang@neurotec.ki.se; Lars-Olof Wahlund - lars-olof.wahlund@neurotec.ki.se; Leif Svensson - Leif@asf.hs.sll.se; Bengt Winblad - bengt.winblad@neurotec.ki.se; Per Julin - per.julin@neurotec.ki.se
*Corresponding author

Published: 12 September 2002
BMC Neurology 2002, 2:9
Received: 6 May 2002
Accepted: 12 September 2002
This article is available from: http://www.biomedcentral.com/1471-2377/2/9
© 2002 Huang et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article’s original URL.

Abstract

Background: Mild cognitive impairment (MCI) was recently described as a heterogeneous group with a variety of clinical outcomes and high risk to develop Alzheimer's disease (AD). Regional cerebral blood flow (rCBF) as measured by single photon emission computed tomography (SPECT) was used to study the heterogeneity of MCI and to look for predictors of future development of AD.

Methods: rCBF was investigated in 54 MCI subjects using Tc-99m hexamethylpropyleneamine oxime (HMPAO). An automated analysis software (BRASS) was applied to analyze the relative blood flow (cerebellar ratios) of 24 cortical regions. After the baseline examination, the subjects were followed clinically for an average of two years. 17 subjects progressed to Alzheimer's disease (PMCI) and 37 subjects remained stable (SMCI). The baseline SPECT ratio values were compared between PMCI and SMCI. Receiver operating characteristic (ROC) analysis was applied for the discrimination of the two subgroups at baseline.

Results: The conversion rate of MCI to AD was 13.7% per year. PMCI had a significantly decreased rCBF in the left posterior cingulate cortex, as compared to SMCI. Left posterior cingulate rCBF ratios were entered into a logistic regression model for ROC curve calculation. The area under the ROC curve was 74%–76%, which indicates an acceptable discrimination between PMCI and SMCI at baseline.

Conclusion: A reduced relative blood flow of the posterior cingulate gyrus could be found at least two years before the patients met the clinical diagnostic criteria of AD.

Background
Mild cognitive impairment (MCI) is an operational diagnostic term developed to describe the preclinical stage of Alzheimer's disease (AD). MCI is a heterogeneous group containing preclinical stage of dementia [1]. The rate at which MCI subjects convert to AD each year is ten times more than the rate for normal subjects [2]. Identification of progressive mild cognitive impairment (PMCI) versus...
non-progressive mild cognitive impairment subjects (SMCI) is currently of great theoretical interest and practical importance. Early therapeutical interventions are more likely to be effective and the improvement of clinical outcome may significantly reduce the heavy economic and social burden.

The utility of functional imaging techniques, such as single photon emission computed tomography (SPECT) and positron emission computed tomography (PET) for the study of regional abnormalities in AD has been established [3,4]. There is agreement that metabolic reduction and hypoperfusion in the parietal, temporal cortex and limbic system are consistent findings in AD that often correlate with cognitive functions [3,4]. However, sensorimotor cortex, pons, and cerebellum were found to be relatively preserved [5,6].

In contrast, functional imaging findings for the preclinical stage of AD are inconsistent [7,8]. Kennedy et al. showed that there was decreased metabolism in the tempo-parietal region in patients before they met the clinical criteria of AD [7]. A marked metabolic reduction in the posterior cingulate gyrus was reported in the transitional stage of AD patients by Minoshima et al. [6]. Kogure et al.’s study used a statistical parametric mapping (SPM) technique for group comparisons and found a significant bilaterally decreased rCBF in the posterior cingulate gyrus and precunei in MCI subjects, as compared to controls at least two years before they met the clinical diagnosis of AD [8]. However, only few studies have looked at the heterogeneity of MCI. Johnson et al. demonstrated that SPECT was a promising method for the diagnosis of PMCI, in which the combination of the cingulate gyrus, hippocampal-amygdaloid complex and thalamus identified more than 80% of the subjects who would progress to AD after a 16.7 month follow-up [9].

The present study assessed baseline regional cerebral blood flow (rCBF), using an automated ROI-based analysis software, in a group of MCI subjects who were followed clinically for about two years. Specifically, we wanted to examine preclinical changes of dementia, and to assess the clinical prediction of dementia and diagnostic accuracy of SPECT for separating PMCI and SMCI at baseline.

**Methods**

**Subjects selection**

Fifty-four MCI patients were evaluated. The patients were selected from all individuals consecutively investigated for suspected dementia at the geriatric clinic, Huddinge University Hospital. Patients were primarily referred from General practitioners. The clinic serves the large Stockholm area with approximately 2 million inhabitants. All subjects with a diagnosis of MCI at the initial investigation were included in the study. Patients with other medical psychiatric diagnosis were excluded. No subject received either psychotropic medication or an acetylcholinesterase inhibitor likely to influence the results of SPECT scanning.

All subjects underwent general medical, neurological, psychiatric and neuropsychological evaluation, as well as neuroimaging diagnostic procedures (SPECT and MRI) at the initial investigation. The subjects were clinically followed for 28.9 ± 16.3 months on average. After the follow-up period, 17 MCI subjects have progressed to AD. These MCI subjects were defined as PMCI. 37 remained MCI and did not fulfill the criteria of dementia during the observation time. These MCI subjects were defined as SMCI. The baseline PMCI and SMCI did not differ with respect to age (PMCI (years): 63.6 ± 7.3, SMCI (years): 60.3 ± 8.5), gender (PMCI (f/m): 9/8, SMCI (f/m): 24/13), follow-up time (PMCI (months) 26.6 ± 19.0, SMCI (months) 29.7 ± 16.6) and MMSE (PMCI: 26.2 ± 2.0, SMCI: 27.0 ± 2.3).

**Diagnosis**

Subjects who were diagnosed as MCI did not fulfill the diagnostic criteria for dementia according to DSM-IV criteria and did not have evidence of impairment in social or occupational functioning, but performed at least 1.5 SD below average for their age on at least one neuropsychological test [10]. Progressive mild cognitive impairment (PMCI) referred to the MCI subjects who converted to Alzheimer’s disease according to the DSM-IV criteria during the follow up and stable mild cognitive impairment (SMCI) was defined as the subjects who still did not fulfill the criteria for dementia according to DSM-IV during the observation time.

**Neuropsychological tests**

All subjects were tested by experienced psychologist with five subtests (Information, Digit Span, Similarities, Block Design and Digit Symbol) from the Wechsler Adult Intelligence Scale-Revised (WAIS-R), Trail Making Test A and B, free and recognition words from the Stockholm Geriatric Research Center (SGRC) [11,12]. The general level of cognition was assessed by the Mini-Mental State Examination (MMSE) [13].

**Single photon emission computed tomography (SPECT)**

Each subject was injected with 1000 M bq Tc-99m-HMPAO (Ceretec, Amersham Ltd) in a quiet surrounding with eyes closed. Acquisition started 30 minutes after injection. Data were collected in 64 projections evenly spread through 360 degrees with a single headed rotating gamma camera (Siemens Diacam) with a total acquisition time of 32 minutes. Tomographic slices were reconstruct-
ed using an iterative algorithm (Hosem, Nuclear Diagnostics AB, Sweden) with Chang attenuation correction (Attenuation coefficient: 0.12 cm⁻¹). Data were formatted as a 3D dataset with 64 × 64 × 64 cubic voxels with 3.5 mm sides. The resolution in a tomographic slice was measured to be 10.2 mm (FWHM). The reconstructed data sets were post-filtered with a Butterworth filter, cutoff 0.7 cm⁻¹.

**SPECT registration and quantification**
Image registration and quantification were performed with the BRASS software developed by Nuclear Diagnostics (London, England and Stockholm, Sweden) [14]. The patient datasets were iteratively registered using 9 parameter linear registration to a normal template using normalized mutual information as similarity function. The software uses a map of 46 volumes-of-interest (VOIs) that encompass the entire brain [15]. The subjects were normalized according to cerebellar cortex. Mean image of PMCI and SMCI and the region map were obtained (figure 1).

The quantification evaluations were performed in 28 cortical regions, since they are the most interesting regions in AD. The region selected were bilateral sensorimotor, occipital, parietal, anterior and posterior dorsal frontal, anterior and posterior orbital frontal, parieto-temporal, medial, lateral and posterior temporal lobe, temporal pole as well as bilateral anterior and posterior cingulate cortex. The relative regional cerebral blood flow (rCBF) in the selected regions were calculated as cerebellar ratios. (Mean value of region/mean value of bilateral cerebellar cortex.)

**Statistics**
The baseline VOI results of PMCI and SMCI subjects were compared using t-test, p < 0.05 was considered to the significant level, uncorrected for multiple comparisons, because of the relative small sample size. The VOIs with significantly different rCBF between groups were entered into a logistic model. Receiver operating characteristic (ROC) analysis was applied for the discrimination between PMCI and SMCI.

**Results**

**Conversion rate**
The conversion rate of MCI to AD was 13.7% per year.

**Brain perfusion of PMCI and SMCI**
The mean and standard deviation of each relative rCBF value was shown in Table 1. The box-and-whisker plots of Left Posterior Cingulate ratio value were shown in figure 2. There was one outlier in SMCI group. T-test was performed within the whole group (W) and after excluding the outlier (O), separately. PMCI group had a significantly decreased rCBF in the left posterior cingulate cortex (0.84 ± 0.07) compared to SMCI (W: 0.91 ± 0.11, t = -2.3529, p = 0.0224, O: 0.92 ± 0.09, t = -3.2602, p = 0.0020). The blood flow of the left parieto-temporal lobe had a tendency to decrease in PMCI (0.88 ± 0.07) compared to SMCI (W: 0.91 ± 0.05, t = -1.8326, p = 0.0726, O: 0.91 ± 0.05, t = -1.9911, p = 0.0518).

**Logistic regression**
The rCBF of left posterior cingulate cortex was entered into a logistic regression model for the differential diagnosis between PMCI and SMCI at baseline within the whole group (Estimate: -7.17 (-13.89, -0.45), Standard Error 3.43, p = 0.037). ROC analysis was performed with 74%
of the area under the curve. An alternative logistic regression was performed after we excluded the outlier (Estimate: -12.41 (-21.10, -3.73), Standard Error 4.43, p = 0.005) and the area under the ROC curve was 76%.

**Discussion**
The present study showed that the conversion rate of MCI to AD was 13.7% per year, which is comparable with other cohorts of MCI-patients [2]. Using a recently developed automated analysis program for rCBF analysis in individual patients, we found posterior cingulate hypoperfusion to be the earliest deficit in the transitional stage of AD. A logistic regression applied for the ROC curve calculation gave an area under the curve of 74%–76% indicating an acceptable discrimination of the posterior cingulate cortex between PMCI and SMCI at baseline.

It was reported in Fox et al's study, using compression mapping of serial magnetic resonance images, that genetically at risks subjects had posterior cingulate atrophy years before the onset of dementia [16]. Our SPECT study was not corrected by MRI. The results could be influenced by partial volume effect. However, several studies found that posterior cingulate had reduced metabolism in preclinical dementia, even after the correction of atrophy [17]. MRI will be performed in our following SPECT study. For the clinical purpose, the current findings might be valuable for the prediction of dementia in the heterogeneous group of subjects presenting with MCI.

Posterior cingulate cortex was found to participate in cognitive functions such as memory and spatial orientation [18]. The associations of the posterior cingulate cortex with medial temporal lobe structures have been demonstrated in previous studies. This might imply a major role in memory-related functions of the cingulate cortex. Area 23a and 29/30 of posterior cingulate afferents terminate in the entorhinal cortex, subiculum has projections to

---

**Figure 2**
Box-and-whisker plots of relative regional blood flow in Left Posterior Cingulate. PMCI: progressive mild cognitive impairment. SMCI: stable mild cognitive impairment.
area 29/30 and parahippocampus also have wide associations with the posterior cingulate region [19,20]. Several investigators showed that the posterior cingulate cortex contributes to the spatial orientation and spatial working memory which might rest on the association of parietal area 7 and parahippocampal gyrus with the spatially selective firing in layer II of entorhinal cortex [18].

Preclinical AD has been reported having the neuropathological features of mild AD, including neurofibrillary tangles and neuritic plaques in the medial temporal lobe [21]. Some studies demonstrated that the initial neuronal lesions develop in the entorhinal cortex [22]. Gomez-Isla et al. reported that the predromal phase of AD patients had a 60% of neuron loss in layer II of the entorhinal cortex and 40% loss in layer IV, as compared to controls [23]. However, no pathological changes have been reported in the posterior cingulate. Based on the above findings, we hypothesize that in the preclinical stage of AD, isolation of the posterior cingulate cortex from the input and output of the medial temporal lobe structures is probably an important mechanism for the deficits of cognitive function seen in PMCI subjects. Such cortico-cortical disconnection might subsequently result in the decreased rCBF found in the posterior cingulate cortex. It was also reported that the antero-dorsal nucleus of the thalamus had pathological changes in preclinical AD [22]. A study of rhesus monkey showed that the antero-dorsal nucleus associates with area 29 of the posterior cingulate gyrus [24]. According to the disconnection hypothesis, a lesion of the antero-dorsal nucleus in transitional AD might also contribute to the subsequent hypoperfusion showed in the posterior cingulate cortex.

A metabolic reduction of the posterior cingulate was also found in lewy body disease, indicating that the involvement of the posterior cingulate might be a common pathophysiological process in neurodegenerative disease [25]. In addition, our study showed that the parieto-temporal association cortex had a relatively mild hypoperfusion in PMCI at baseline. However, previous studies have indicated that hypoperfusion of the parieto-temporal cortex was a typical and consistent finding in AD, which suggests that the parieto-temporal association cortex might be only slightly affected at the preclinical stage of dementia, but significantly develops as the disease spreads [8].

**Conclusion**

Topographical analysis of rCBF in preclinical AD using SPECT and an automated VOI-based analysis could show a reduced relative blood flow in the posterior cingulate cortex at least two years before the subjects with MCI met the clinical diagnostic criteria of AD. Cingulate hypoperfusion is a promising marker for the early detection of AD in the heterogeneous group of subjects presenting with mild cognitive impairment.

**Competing interests**

None declared.

**Authors’ Contributions**

CH, participated in the design of the study, carried out the SPECT analysis, statistical analysis and drafted the manuscript. L-OW, participated in the design and coordination, was responsible for the evaluation of clinical diagnosis and in the general supervision of the project. LS, was responsible for SPECT examinations, SPECT data basing and participated in the SPECT image analysis. BW, participated in the design and coordination of the study. PJ, conceived of the study and participated in the design, coordination and supervised the SPECT image and statistical analysis. All authors read and approved the final manuscript.
Acknowledgments

This work was supported by the Swedish Medical Research Council, the Swedish Council for Social Research, the Greta Lindenauf-Hansell’s Foundation, the Karolinska Institute and the Swedish Society of Medicine. Perry Radau and Nuclear Diagnostics Ltd are gratefully acknowledged for the generous support and cooperation regarding the BRASS program.

References

1. Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO: Mild cognitive impairment – an early stage of Alzheimer’s disease? J Neurotransm Suppl 1998, 54:21-29
2. Petersen RC, Smith GE, Waring SC, Ikonomidis J, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308
3. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE, Hieshima K: The scintigraphic appearance of Alzheimer’s disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 1992, 33:181-185
4. Syed GM,nięer J, Barrett J, Levy R: Patterns of regional cerebral blood flow in Alzheimer’s disease. Nucl Med Commun 1992, 13:656-663
5. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsi SY: The fluoro-deoxyglucose 18F scan in Alzheimer’s disease and multi-Infarct dementia. Arch Neurol 1985, 42:71-174
6. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997, 42:85-94
7. Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward AM, de Quervain D, Roques P, Lewington G, Cunningham VJ, Rossor MN: Metabolic reduction in the posterior cingulate cortex in early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med 2000, 41:1155-1162
8. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Slatin A, Albert MS: Preclinical prediction of Alzheimer’s disease using HMPAO SPECT. Neurology 1998, 50:1563-1571
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington: American Psychiatric Association 1994
10. Wechsler D: Wechsler Adult Intelligence Scale-Revised Manual. San Antonio: Psychological Corp 1981
11. Backman L, Forsell Y: Mild cognitive impairment: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1992, 26:256-270
12. Backman L, Forsell Y: Mild cognitive impairment: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1992, 26:256-270
13. Folstein MF, Folstein SE, McHugh PR: "Mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198
14. Radau PE, Slomka PJ, Julin P, Svensson L, Wahlund LO: Automated segmentation and registration technique for HMPAO SPECT imaging of Alzheimer’s patients. Medical imaging 2000: Image processing, Kenneth M. Hansson, Ed. Proceedings of SPIE 2000, 435-443
15. Radau PE, Slomka PJ, Julin P, Svensson L, Wahlund LO: Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. J Med Phys 2001, 28:1660-1668
16. Fox NC, Crum WR, Scabhill RJ, Stevens JM, Janssen JC, Rossor MN: Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001, 358:201-205
17. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996, 334:751-758
18. Vogt BA, Finch DM, Olson CR: Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 1992, 2:435-443
19. Rosene DL, Van Hoesen GW: Hippocampal efferents reach widespread areas of cerebral cortex and amygdala in the rhesus monkey. Science 1977, 198:215-217
20. Insausti R, Amaral DG, Cowan WM: The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol 1987, 264:356-395
21. Hof PR, Brier LM, Perl DP, Delacourte A, Buee L, Bouras C, Morris JH: Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol 1992, 49:946-953
22. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259
23. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT: Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 1996, 16:4491-4500
24. Vogt BA, Pandya DN, Rosene DL: Cingulate cortex of the rhesus monkey: I. Cytoarchitecture and thalamic afferents. J Comp Neurol 1987, 262:256-270
25. Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA: Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996, 47:462-466

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/2/9/prepub